The non-steroidal anti-in¯ammatory drug sulindac is used in cancer prevention and therapy, but the molecular aspects of its anti-tumor eect remain unresolved. In vivo the prodrug sulindac, is converted into the metabolite sulindac sul®de. We found that sulindac sul®de strongly inhibits Ras induced malignant transformation and Ras/ Raf dependent transactivation. Sulindac sul®de decreases the Ras induced activation of its main eector, the cRaf-1 kinase. In vitro sulindac sul®de directly binds to the Ras gene product p21ras in a non-covalent manner. Moreover, we can show that sulindac sul®de inhibits the interaction of p21ras with the p21ras binding domain of the Raf protein. In addition, sulindac sul®de can impair the nucleotide exchange on p21ras by CDC25 as well as the acceleration of the p21ras GTPase reaction by p120GAP. Due to its action at the most critical site in Ras signaling we propose sulindac sul®de as a lead compound in the search for novel anti-cancer drugs which directly inhibit Ras mediated cell proliferation and malignant transformation.
Introduction
Sulindac and other non-steroidal anti-in¯ammatory drugs (NSAIDs) reduce the risk of cancer development (Giardiello, 1994; Luk, 1996) . NSAIDs aect the eicosanoid pathway by the inhibition of two key enzymes: cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX2) (Vane and Botting, 1996) . High levels of eicosanoids increase the proliferation rate of carcinoma cells in vitro and in vivo . The chemoprevention of colon carcinogenesis by sulindac is accompanied by a decrease in the levels of cyclo-oxygenase metabolites (Rao et al., 1995) . Physiologically, the prodrug sulindac is reversibly metabolized into sulindac sul®de that eectively inhibits COX2, or irreversibly into sulindac sulfone. The inhibition of apoptosis of cultured intestinal cells by overexpression of COX2 can be reversed by sulindac sul®de (Tsujii and DuBois, 1995) .
There are several evidences that the cytostatic eect of sulindac cannot only be explained by the inhibition of prostaglandin synthesis: The addition of prostaglandins to a cell line that lacks the capacity to synthesize prostaglandins cannot reverse the antiproliferative eect of sulindac sul®de (Hanif et al., 1996) . Sulindac and its metabolites inhibit cell growth and carcinogenesis independently from eicosanoid metabolism Piazza et al., 1995 Piazza et al., , 1997a . Sulindac causes apoptosis in epithelial tissue and cultured cancer cells with no apparent involvement of prostaglandins (Pasricha et al., 1995; Piazza et al., 1997b) . Sulindac is used in the therapy and the prevention of tumors in patients with the inherited cancer predisposition Familial Adenomatous Polyposis (FAP) (Pasricha et al., 1995; Winde et al., 1995) . Experiments performed with the Min mouse, the animal model for FAP, revealed that the anti-tumor eect of sulindac is independent of prostaglandin biosynthesis (Chiu et al., 1997) . Sulindac sulfone seems to target tumors carrying mutations in the proto-oncogene Ras more eectively than tumors carrying the wild type Ras gene (Thompson et al., 1997) . Despite these ®ndings however, the molecular basis of the eect of sulindac and its metabolites remains largely unsolved. Here we present evidence that the active metabolite ± sulindac sul®de ± can inhibit Ras mediated signal transduction, which is one of the most important pathways involved in malignant transformation (Bos, 1989) .
Results

Sulindac sul®de inhibits Ras induced transformation
The experiments of Thompson et al. (1997) pointed to the possibility that the NSAID sulindac may interfere with the p21ras initiated signal transduction pathway. Therefore, we wanted to test the eect of sulindac sul®de which is the active physiological metabolite of sulindac on Ras mediated transformation of primary ®broblasts. Activated H-ras can cooperate with other oncogenes such as Myc or SV40 large T-Antigen (SV40 T-Ag) and also with positive G1 regulators as D-or Etype cyclins or CDK4 in the process of malignant transformation which can be demonstrated by focus formation of transfected primary Rat embryo fibroblasts (REFs) (Land et al., 1983; Lovec et al., 1994; Haas et al., 1997a,b) . We transfected the expression construct for SV40 T-Ag (Haas et al., 1997a) together with the pGEJ6.6 H-ras (H-rasG12V) expression construct (Land et al., 1983) into primary REF cells and scored for focus formation in the absence or in the presence of dierent concentrations of sulindac sul®de. Four dierent experiments were performed and in each 2.5610 5 transfected REF cells were assayed. In each experiment, focus formation was scored without drug, with vehicle only (0.5% DMSO) or in the presence of vehicle and varying concentrations of sulindac sul®de. We observed that focus formation was clearly inhibited at concentrations between 10 and 50 mM drug concentration (Table 1) . Similar inhibition of focus formation was obtained in experiments where activated H-ras was used in combination with c-Myc or cyclin E expression constructs (not shown) suggesting that sulindac sul®de speci®cally interferes with p21ras signaling and inhibits p21ras mediated transformation of ®broblasts.
To exclude that the inhibitory eect of sulindac sul®de on p21ras induced focus formation is due to the inhibition of cell proliferation or a general cytotoxic eect of the drug the proliferation rates of two dierent, unrelated cell types, NIH3T3 ®broblasts and Saos epithelial cells, were assayed in dependence of increasing sulindac sul®de concentrations. In this assay sulindac sul®de had no eect on cell proliferation up to 125 mM (Figure 1 ). However, in the REF transformation assay we had found that H-ras induced focus formation was strongly inhibited at concentrations between 10 and 50 mM (Table 1) . These results suggest that the inhibition of Ras induced focus formation by sulindac sul®de is not due to an inhibitory eect on cell proliferation or a cytotoxic eect of the drug, and imply a direct eect of sulindac sul®de on p21ras function. All following cell culture assays were performed at or below the drug concentration of 100 mM to exclude any unspeci®c eects of sulindac sul®de on cell proliferation.
Sulindac sul®de inhibits Ras induced transactivation
To be able to more directly measure the eect of sulindac sul®de on the Ras signaling pathway, we performed reporter gene assays using RK13 cells. The reporter gene luciferase was driven by a basal TK promotor and a SRE element which allows transcriptional transactivation through the ternary complex factor upon stimulation of the Ras/Raf/MEK/Erk cascade (E74 reporter, Block et al., 1996; Jahnknecht, 1996) . Transient transfection assays were performed with constructs expressing the activated H-ras (H-ras G12V) or the constitutively active form of Raf, Raf-CAAX, which is a direct eector molecule downstream of p21ras. With activated H-ras, the SRE dependent transcriptional transactivation of the E74 reporter could be stimulated about 20-fold as expected ( Figure  2a ). Whereas the presence of sulindac sul®de did not aect the basal activity of the reporter gene, the drug was able to reduce the H-ras induced stimulation by over 60% (Figure 2a ). Sulindac itself had no eect in this assay. Next, we asked whether sulindac sul®de acts up-or downstream of p21ras. To test this we used Raf in a constitutively activated form, Raf-CAAX, for transfection (Stokoe et al., 1994; Leevers et al., 1994) . Again, about 30-fold stimulation of SRE dependent transcriptional transactivation compared to vector controls was achieved by cotransfecting Raf-CAAX and the E74 reporter gene construct into RK 13 cells (Figure 2b ). However, in this setting, no signi®cant inhibition of reporter gene activity could be observed in the presence of sulindac sul®de (Figure 2b ). This strongly suggested that sulindac sul®de acts directly on the p21ras molecule and interferes with its activity, very probably by inhibiting the interaction between p21 ras and its downstream eector c-Raf.
Sulindac sul®de inhibits c-Raf kinase activity induced by oncogenic p21ras
To further delineate the eects of sulindac sul®de we tested whether the catalytic activity of c-Raf which is induced by active p21ras can be blocked by sulindac sul®de. Human embryonic kidney cells (HEK293) were transfected with HA-tagged c-Raf-1 together with a construct expressing activated H-ras (H-rasGl2V). After transfection cells were lysed and Raf containing complexes were immunoprecipitated and used for a kinase assay with recombinant kinase dead MEK (MEK-K79M) as a substrate (Figure 3a) whereas the amount of Raf in the immunoprecipitates was controlled by Western blot (Figure 3b) . Cotransfection with activated H-ras increased the kinase activity of Raf more than 20-fold over baseline (Figure 3a,c) . Whereas the prodrug sulindac had no eect on Raf kinase activity, pretreatment of transfected cells with (Table 1) . This ®nding provides additional evidence that sulindac sul®de inhibits p21ras activity and strongly suggests that the molecular basis of this inhibition is probably a direct interaction of the drug with p21ras at the site where the interaction with its downstream eector c-Raf takes place.
Sulindac sul®de binds reversibly to p21ras
To test the possibility that the protein p21ras might be the direct target of sulindac sul®de, the binding of this substance to p21ras was tested by equilibrium dialysis in vitro. The p21ras protein in its active GppNHp bound state was dialyzed against sulindac or sulindac sul®de ( Figure 4a ). The binding curves of the drugs diered strikingly indicating that only sulindac sul®de binds to p21ras. The interaction between p21ras and sulindac sul®de shows saturation at concentrations of about 100 mM ( Figure 4a ). To test whether the binding of sulindac sul®de to p21ras is reversible, the proteindrug complex was dialyzed against an excess of PBS. Sulindac sul®de could be removed nearly completely by this method (Figure 4b ). The dialyzed protein showed a mass identical to p21ras as determined by electrospray ionization mass spectroscopy con®rming reversibility of the interaction with sulindac sul®de (not shown). Drug binding did not lead to the denaturation of p21ras, as shown by measurement of the nucleotide binding by HPLC and of the intrinsic GTPase activity in the presence of a large excess (250 mM) sulindac sul®de ( Figure 4c ). The data represent further evidence for a direct interaction of sulindac sul®de with p21ras.
Sulindac sul®de changes the biochemical properties of p21ras
The observed downregulation of the p21ras signaling pathway by sulindac sul®de and the evidence for a direct binding of the drug to p21ras led us to question whether the binding of sulindac sul®de interferes with the interaction between p21ras and its eector protein cRaf or its activator protein p21rasGEF (CDC25). The in¯uence of sulindac sul®de on these interactions was analysed by¯uorescence spectroscopy ( Figure 5a ,b). For measurement of nucleotide exchange activation and of eector protein binding previously documented protein fragments of CDC25 and c-Raf-1 were used: the catalytic domains of CDC25 (Lenzen et al., 1995) and the p21ras binding domain (RBD) of Raf . The measurements of the interactions of CDC25 and Raf with p21ras are based on the ®ndings that nucleotide dissociation from p21ras is accelerated by binding to CDC25 (Lenzen et al., 1995) and is inhibited by binding to eector molecules like Raf . For the binding studies with CDC25 and Raf-RBD p21ras was loaded with uorescent mant-GDP or the non-hydrolyzable GTPanalog mant-GppNHp, respectively (Schweins et al., 1996) . The¯uorescent label mant (N-methylanthraniloyl) is covalently linked to the ribose moiety of these nucleotides. These nucleotide analogs allow measurement of the nucleotide dissociation rates by means of uorescence spectroscopy. The nucleotide dissociation was initiated by the addition of 100-fold excess of GppNHp or GDP The assay buer was 50 mM Tris/ HCl (pH 7.4), 5 mM MgCl 2 . The¯uorescence decay due to mant-nucleotide dissociation (l ex =385 nm, l em =450 nm) was ®tted by a single exponential function yielding k obs . These experiments demonstrated that sulindac sul®de strongly inhibited the interactions between p21ras and CDC25 and Raf (Figure 5a,b) . The prodrug sulindac had no eect (not shown).
Recent structural studies had shown that the regions of the p21ras protein which interact with the down- stream eector Raf and the GTPase activating proteins (GAPs) partly overlap (Nassar et al., 1995; Schezek et al., 1997) . In addition, the alteration of the GTPase acceleration would give new hints for the change of the biochemical characteristics of p21ras by sulindac sul®de. Therefore the in¯uence of sulindac sul®de on the acceleration of the p21ras GTPase reaction by the catalytic domain of its main GTPase activating protein (pl20GAP) was tested and was compared to the two other small guanine nucleotide binding proteins Rho and Ran. To this end, 50 mM of the respective small Gprotein (i.e. p21ras, Rho or Ran) in their GTP bound state were incubated with 50 nM of its corresponding GAP in presence of dierent concentrations of sulindac sul®de in 150 ml assay buer (50 mM Tris/HCl (pH 7.4), 5 mM MgCl 2 ) at 208C. Aliquots were taken every 2 min over a period of 30 min and the amount of GTP and GDP was quanti®ed by analytical HPLC as described (Schweins et al., 1996) . Sulindac sul®de had a strong inhibitory eect on the activation of the GTPase by p120GAP (Figure 5c ). However, no eect of the drug was observed on the GTPase activities of the Ras like small G-proteins Ran and Rho in the presence of RanGAP or RhoGAP, respectively (Figure 5c ). These ®ndings not only provide additional and strong evidence that sulindac sul®de binds to p21ras and inhibits its biochemical functions but also demonstrate clearly the speci®city of the drug for the p21ras molecule.
Discussion
The NSAID sulindac is used in chemoprevention of colon tumorigenesis but the molecular basis of its function remains unclear. Circumstantial evidence pointed to the possibility that sulindac may interfere with p21ras signaling. We have demonstrated here that the active metabolite of the prodrug sulindac namely sulindac sul®de can indeed block p21ras mediated cellular processes and biochemical functions of the protein. We present evidence that this is due to a direct interaction of the drug with p21 ras.
Sulindac sul®de had a clear inhibitory activity on Hras/SV40 T-Ag induced REF cell transformation. This could have been also due to a general eect on cell proliferation or a cytotoxic eect of the drug. However, this was ruled out by comparing the concentrations of the drug that are active in an MTT assay and in the REF focus assay. The eect of sulindac sul®de on cell proliferation was manifest only rate constant (k obs ) at 378C for 0.5 mM p21ras-mantGppNHp in the presence of 1.0 mM p21ras binding domain of Raf (Raf-RBD) was measured as a function of sulindac sul®de concentration. At sul®de concentrations higher than 250 mM k obs reaches the value of the dissociation rate constant in the absence of Raf-RBD) (dashed line) indicating complete inhibition of the interaction between p21ras and its eector Raf. In experiments A and B the prodrug sulindac has no eect up to 500 mM (not shown). (c) Activation of the intrinsic GTPase of p21ras and the Ras-like proteins Ran and Rho by their corresponding GAPs in the presence of sulindac sul®de. Sulindac sul®de inhibits the GTPase activation of p21ras by p120GAP. There is no eect on the GTPase activation of Ran and Rho by RanGAP or RhoGAP, respectively. Sulindac has no eect (not shown) at 120 mM, whereas the reduction of focus formation is clearly observed at much lower concentration, i.e. between 10 and 50 mM. This makes it very unlikely that the observed inhibition of focus formation is due to a general eect of sulindac sul®de on cell proliferation or due to unspeci®c cell death provoked by the drug. In addition, an eect of sulindac sul®de on focus formation was not only observed in a cotransfection of H-ras and SV40 T-Ag but also in transfections where the combinations of H-ras and Myc or H-ras and Cyclin E were used which provided further evidence that the eect of sulindac sul®de is due to an interference of the drug with p21ras function.
More evidence that supported our view that sulindac sul®de can interfere with p21ras mediated signal transduction came from reporter gene assays that assayed the Ras/Raf dependent transcriptional transactivation of an SRE dependent promotor. In this assay sulindac sul®de had a strong inhibitory eect on Ras/ Raf dependent transcriptional transactivation when the stimulation was done with activated H-ras but the drug showed no eect on transactivation when Raf-CAAX, a constitutively activated form was transfected (Stokoe et al., 1994; Leevers et al., 1994) . Additionally, sulindac sul®de directly inhibited p21ras dependent activation of the Raf kinase in a kinase assay. These results made it very likely that sulindac sul®de functions upstream of Raf but downstream of Ras and suggested a direct in¯uence on p21ras itself as well as an inhibitory activity of the drug on Ras/Raf interaction. Interestingly, the concentrations of sulindac sul®de that were active in inhibiting Raf kinase activity correlated well with the concentrations that showed inhibition in the REF focus forming assay. This represents another piece of evidence that the inhibition of the p21ras mediated signal transduction cascade and more precisely the interaction of p21ras and the Raf kinase is the target of sulindac sul®de. As a further support for this hypothesis, data of an equilibrium dialysis experiment and a¯uorescence binding assay showed that sulindac sul®de directly binds to p21ras and inhibits the interaction between p21ras and Raf kinase in vitro. In another biochemical assay we showed that sulindac sul®de inhibits also the activation of p21ras by the nucleotide exchange activating protein CDC25. Moreover, since the regions of the p21ras protein which interact with Raf and the GTPase activating proteins partly overlap, we measured the eect of sulindac sul®de on the GTPase activation by p120GAP to get another con®rmation for its molecular mechanism. The observed inhibitory eect on the GTPase activation was not due to the blockage of the intrinsic p21ras GTPase activity indicating that the interaction between p21ras and p120GAP is directly aected by sulindac sul®de. Most importantly, measuring the interaction between p21ras and p120GAP we could show that sulindac sul®de is speci®c for p21ras and does not aect other small guanine nucleotide binding proteins as Ran or Rho. This ®nding is of particular importance since it demonstrates the selectivity of sulindac sul®de for the p21ras molecule and the corresponding signaling pathway. This specificity underscores the potential for sulindac sul®de as a lead structure for the development of new anti-cancer drugs that target p21ras signal transduction.
Taken together, three inhibitory eects of sulindac sul®de could be shown in vitro: (1) a block of the interaction between p21ras and its major downstream target protein Raf kinase; (2) a block of the activation of p21ras by the nucleotide exchange protein CDC25; and (3) a block of the p120GAP-induced activation of the p21ras GTPase activity. In vivo these eects are not contradictory: as long as the p21ras binding to its eector is blocked it is irrelevant whether p21ras is in the active GTP-state or in the inactive GDP-state; in either situation the net-eect will be an inhibition of the p21ras-mediated signaling as observed in the transformation, transactivation and Raf kinase assays described in this study. Furthermore, in tumor cells, the signaling by oncogenically active p21ras (e.g. p21rasG12V) is uncoupled from the regulatory GTPase activation and is assumed to be well targeted by sulindac sul®de.
Why are the eective concentrations of sulindac sul®de in the in vitro binding experiments and the biochemical assays higher than in the performed assays using cultured cells? This apparent inconsistency can be explained by the chemical nature of sulindac sul®de and the microenvironment of the membrane bound protein p21ras. The hydrophobicity of sulindac sul®de might lead to its enrichment in the cell membrane and thus to a higher eective drug concentration in the microenvironment of p21ras than in aqueous solution. Thus in the absence of membrane structures in biochemical assays higher concentrations of the drug may be needed to achieve the same eects as in cells where the lipid bilayer of the membranes provide a suitable interface for interaction between sulindac sul®de and p21 ras.
Our results demonstrate that sulindac sul®de inhibits Ras mediated signaling in addition to its known eect on the eicosanoid pathway. These actions may not be independent since certain lipids including arachidonic acid and dierent eicosanoids not only bind to the p21ras GTPase activating proteins p120GAP and NF1 GAP but also regulate their activities (Tsai et al., 1989; Bollag and McCormick, 1991; Golubic et al., 1991; Han et al., 1991) . The interaction of a sulindac metabolite with key proteins of two dierent, but connected mitogenic pathways provides an explanation for the potent anti-proliferative eects of sulindac. Since Ras signaling is linked to the regulation of cellcycle progression (Peeper et al., 1997) , our results are also consistent with the ®nding that sulindac causes a cell cycle block independently from the eicosanoid pathway (Goldberg et al., 1996) .
The inhibitory eects on the Ras pathway are only seen at high micromolar sulindac sul®de concentrations what might limit the clinical relevance of our results. Nevertheless, our ®ndings explain the high eectiveness of sulindac in suppository treatment of FAP patients where presumably very high drug concentrations are locally reached in the colon (Winde et al., 1995) considering that the daily dose is 1.5 g sulindac per patient. Furthermore, due to the high eective concentration it seems impossible to inhibit intracellular Ras signaling completely by sulindac. Since a base level of p21ras function can be considered as essential for any living cell, this complete inhibition would lead to harmful side eects and should be avoided during drug treatment.
To our knowledge this is the ®rst report describing an anti-cancer drug which directly aects the oncoprotein p21ras and its biochemical properties. This study together with others' ®ndings showed that sulindac sul®de inhibits two intracellular proliferation regulating pathways, which makes this drug a promising lead compound for the design and the search for a new generation of anti-cancer drugs.
Materials and methods
Drugs
Sulindac was purchased from Sigma (Deisenhofen, Germany). Sulindac sul®de was kindly provided by MSD Sharp & Dohme (Haar, Germany). The drugs were dissolved in DMSO as 10006stock solutions. In all experiments DMSO controls showed no signi®cant eects. UV-spectra of the compounds in PBS were recorded and extinction coecients were determined at the wavelengths of their maximal absorptions: sulindac 12 500 M 71 cm 71 at 326 nm and sulindac sul®de 15 900 M 71 cm 71 at 347 nm. The linear correlation between drug concentration and UV-absorption at the characteristic maximal wavelength revealed no hints of insolubility or micelle formation in buered aqueous solutions up to 500 mM for sulindac sul®de and up to 2.5 mM for sulindac.
Transformation assays
Preparation of primary rat embryonic ®broblasts and transfections were done as described (Lovec et al., 1994) . For each sulindac sul®de concentration and for the control 10 6 REF cells were transfected with 15 mg H-ras and 15 mg SV40 T-Ag and were split 1 : 4 after 24 h. Medium was changed every 24 h with fresh drug or vehicle, respectively. Foci were counted 8 days post transfection. At concentrations at and above 150 mM, a loss of cells was observed as expected considering the data of the MTT assay.
Cell proliferation/cytotoxicity assay
Assays were essentially done as described (Mosmann, 1983) . Brie¯y, cells were cultivated in¯at bottom 96-well plates in 200 ml DMEM with 10% fetal calf serum, 100 IU penicillin/ml and 100 mg streptomycin/ml. The wells at the border of the plates were not used to reassure constant growth conditions for all wells by being surrounded by a liquid ®lled neighboring well. At the end of the culturing time half of the medium was removed from all wells and 10 ml medium without serum containing 5 mg/ml MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide from Sigma, Deisenhofen, Germany) was added to each well. After 3 h incubation cells were lysed by adding 100 ml of a 2-butanol : 2-propanol : 1 M HCl mixture (16/8/1, v/v/v). The plates were submitted to the analysis of the absorption at 540 nm in a microplate reader (Biorad, Munich, Germany). The median of the values for the ®rst row of wells was used as reference. Tests were all performed in triplicate on each plate. An initial determination of the growth curves for dierent cell numbers per well over 0 ± 4 days was performed to determine the best number of cells per well to give nearly linear growth curve. Next the cytotoxicity-assay was performed over three days with medium change every 24 h. The growth inhibition was calculated as percent of the values for the control without drug and without vehicle. The highest amount of vehicle (DMSO) reduced the growth to 87.9%+7.3 (mean of 42 experiments) compared to the control. Each experiment was performed in triplicates on each plate and each experiment was repeated three times.
Reporter gene assays
Reporter gene assays were performed as described (Block et al., 1996) . Rabbit kidney epithelial like RK13 cells were grown to 25% con¯uency on 6 cm dishes and then transfected with a total of 10 mg DNA by the calcium phosphate coprecipitation method. We used 2 mg reporter construct E74 3 -tk80-luc, 0.5 mg b-galactosidase expression vector (pEQ176), 1.5 mg ERK-1 expression vector, 1.5 mg ETS protein expression vector (pEV-ER81) and 1.5 mg pcDNA3-Raf or pcDNA3 empty expression plasmid. Where indicated, 80 ng RSV Ras-G12V plasmid or 25 ng pcDNA3-Raf-CAAX plasmid were transfected. After transfection cells were incubated with 100 mM sulindac or sulindac sul®de. Thirty-six hours after transfection, cells were harvested and lysed and luciferase and b-galactosidase activities were determined (Janknecht et al., 1993) . Relative luciferase activity was obtained by normalizing luminescence to b-galactosidase activity.
Raf kinase assay
The nucleotide sequence coding for a 11 amino acids hemagglutinine tag (HA-tag; amino acid sequence MAYPYDDVPDYA) was introduced in-frame into the N-terminus of wild type c-Raf and c-RafR89L in pcDNA3 (Cravchik and Matus, 1993) . Construction of pcDNA cRafwt and c-RafR89L constructs have been described elsewhere (Block et al., 1996) . HEK 293 cells were grown up to 50% con¯uency and transfected by the conventional calcium phosphate precipitation method. For each transfection 5 mg of HA-tagged wildtype c-Raf-1, cRafR89L or empty expression vector were used together with 50 ng of RasG12V in pcDNA3. Cells were starved for 36 h in DMEM containing 0.3% fetal calf serum and harvested 48 h after transfection. Sulindac or sulindac sul®de was added to the cell culture medium 1 h before cell harvest at the indicated concentrations. For Raf kinase assays cells were lysed in 25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM Na-pyrophosphate, 25 mM Naglycerophosphate, 2 mM EDTA, 2 mM EGTA, 10% glycerol, 1 mM PMSF, 2 mM pepstatin, 1 mM NaVO 4 , 0.01% aprotinine, 1% NP40 and cleared by centrifugation at 16 000 g for 30 min. For each immunoprecipitation 3 mg of anti-HA monoclonal antibody (clone 12-CA-5) was preabsorbed on protein A agarose beads (Boehringer Mannheim, Mannheim, Germany) and mixed with the lysate for 2 h. Kinase assays were performed as described using recombinant kinase-inactive MEK-1 (MEK-K79M; 1 mg per assay) as a substrate (Flory et al., 1998; Wixler et al., 1996) . Kinase reaction was performed for 20 min in the presence of [g 32 P]ATP and stopped by the addition of Laemmli buer. Proteins were separated on an SDS ± PAGE gel and blotted onto nitrocellulose. MEK-1 phosphorylation was visualized by autoradiography and analysed with a phosphoimager (Fuji, Frankfurt, Germany). After exposure, membranes were probed with cRaf-1 antiserum (Wixler et al., 1996) and developed using enhanced chemoluminescence (Amersham, Braunschweig, Germany) to visualize protein content of transfected cRaf-1.
Source of proteins
p21ras was expressed in E. coli, puri®ed and loaded with GTP or the non-hydrolyzable GTP analog GppNHp (Schweins et al., 1996) . The catalytic domains of p120GAP and NF1GAP were provided by R Ahmadian; the nucleotide exchange factor CDC25 was provided by R Cool Gideon et al., 1992) . The small G-proteins Ran and Rho together with their corresponding GAPs were provided by J Kuhlmann and R Pogge von Strandmann.
Binding assays
For equilibrium dialysis experiments 50 mM p21ras in the GppNHp-state were dialyzed at 208C in presence of sulindac or sulindac sul®de in 200 ml PBS in an equilibrium dialysis apparatus (Hoefer, San Francisco, USA). In preliminary experiments the approximate time for drug equilibrium between the reservoirs separated by a dialysis membrane with a cuto of 10 000 kD was determined to be 18 h. After 24 h drug and protein concentrations were measured by spectroscopic analysis in all chambers and the concentrations of bound and unbound drugs were calculated (Wright et al., 1996) . For dialysis against an excess of buer 50 mM p21rasGppNHp was incubated for 1 h with 250 mM sulindac sul®de and subsequently dialyzed against a 10006volume of PBS at 208C. Aliquots were taken and the sul®de concentration was determined.
Biochemical assays
Experiments were essentially done as described (Lenzen et al., 1995; Herrmann et al., 1995 Herrmann et al., , 1996 Schweins et al., 1996) .
